New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors
Authors
Keywords
-
Journal
RHEUMATOLOGY
Volume 50, Issue 9, Pages 1542-1550
Publisher
Oxford University Press (OUP)
Online
2011-05-27
DOI
10.1093/rheumatology/ker192
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib
- (2013) Drugs in research & development
- Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
- (2010) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents
- (2010) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
- (2010) Richard J. Riese et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- New Btk inhibitor holds promise
- (2010) Rudi W Hendriks Nature Chemical Biology
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
- (2010) Michael E. Weinblatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: A prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register
- (2010) Johannes C. Schrama et al. ARTHRITIS CARE & RESEARCH
- A Rac1 inhibitory peptide suppresses antibody production and paw swelling in the murine collagen-induced arthritis model of rheumatoid arthritis
- (2010) Joana RF Abreu et al. ARTHRITIS RESEARCH & THERAPY
- Induction of Macrophage Migration Inhibitory Factor in ConA-Stimulated Rheumatoid Arthritis Synovial Fibroblasts through the P38 MAP Kinase-Dependent Signaling Pathway
- (2010) Hae-Rim Kim et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
- (2009) J H Coombs et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy
- (2009) R E Alten et al. ANNALS OF THE RHEUMATIC DISEASES
- "Go upstream, young man": lessons learned from the p38 saga
- (2009) D Hammaker et al. ANNALS OF THE RHEUMATIC DISEASES
- Primary B Cell Immunodeficiencies: Comparisons and Contrasts
- (2009) Mary Ellen Conley et al. Annual Review of Immunology
- Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis
- (2009) Stanley B. Cohen et al. ARTHRITIS AND RHEUMATISM
- Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies
- (2009) Nemanja Damjanov et al. ARTHRITIS AND RHEUMATISM
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Prospective new biological therapies for rheumatoid arthritis
- (2009) Ladislav Šenolt et al. AUTOIMMUNITY REVIEWS
- Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
- (2008) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
- Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
- (2007) H K Genant et al. ANNALS OF THE RHEUMATIC DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started